Jincai xue,qinjiang liu,youxin tian,xiaofeng hou. Clinical significance of BRAFV600E and TERT promoter mutation in papillary thyroid microcarcinoma. Oncol Transl Med, 2019, 5: 75-79. |
Clinical significance of BRAFV600E and TERT promoter mutation in papillary thyroid microcarcinoma |
Received:October 27, 2018 Revised:May 29, 2019 |
View Full Text View/Add Comment Download reader |
KeyWord:papillary thyroid microcarcinoma (PTMC); BRAFV600E; TERT; mutation |
Author Name | Affiliation | E-mail | Jincai xue | Gansu Province Tumor Hospital | xuejcky@163.com | qinjiang liu | Gansu Province Tumor Hospital | LIUQJ99@126.com | youxin tian | Gansu Province Tumor Hospital | | xiaofeng hou | Gansu Province Tumor Hospital | |
|
Hits: 6010 |
Download times: 6913 |
Abstract: |
Abstract:Objective The objective of this study was to analyze the correlation between BRAFV600E and TERT
promoter mutations and papillary thyroid microcarcinoma (PTMC) risk factors, and their importance in the
risk assessment of papillary thyroid microcarcinoma.
Methods This study retrospectively analyzed 107 cases of PTMC, which were diagnosed after the
surgery in the department of head and neck surgery in Gansu Province Tumor Hospital from October 2014
to June 2016. The mutations of BRAFV600E and TERT promoter were detected by PCR direct sequencing.
We analyzed the data using χ2 test and binary Logistic regression analysis.
Results Among 107 patients with PTMC, the BRAFV600E and TERT promoter mutation rates were 68.2%
and 11.2%, respectively. Single factor analysis showed that there was a significant difference between the
presence of membrane invasion, lymph node metastasis, and BRAFV600E mutations (P < 0.01). The age,
gender, thyroid capsular invasion, poor pathologic subtype, and lymph node metastasis of patients, was
significantly associated with the TERT promoter mutation (P < 0.05) and the coexistence of the BRAFV600E
and TERT promotor mutations; although, there was a difference between the association of these factors
with the TERT promoter mutation and the association of these factors with the coexistence of the BRAFV600E
and TERT promotor mutations. The multifactorial analysis showed that the factors closely related to the
BRAFV600E mutation included capsular invasion (P = 0.012) and lymph node metastasis (P = 0.000). The
following factors were closely associated with the TERT promoter mutant: male (P = 0.004), aged < 45 years
(P = 0.026), capsular invasion (P = 0.004), pathological subtype (P = 0.030), and lymph node metastasis (P
= 0.043). The following factors were closely related to the simultaneous mutation of BRAFV600E and TERT:
male (P = 0.022), capsular invasion (P = 0.023), poor pathological subtype (P = 0.041), and lymph node
metastasis (P = 0.030).
Conclusion The risk of recurrence increases significantly when mutations in BRAFV600E and TERT
promoters occur simultaneously in PTMC and may have adverse outcomes. Combined detection of
BRAFV600E and TERT promoter mutations is of great value in risk assessment of PTMC. |
Close |
|
|
|